International Journal of Advances in Medical Biotechnology - IJAMB

Effect of Nb2O5 on the aging and cytotoxicity of ZrO2-Y2O3 based biomaterial

Julio Carvalho de Paiva — 2026-05-29

Antibacterial activity of chitosan-based electrospun membranes: applications, challenges, and future trends

Fernanda Hohana Almeida e Sá — 2026-05-22

Chitosan is a polysaccharide with promising industrial and biomedical applications, owing to its intrinsic electrostatic interactions with negatively charged cells, providing outstanding antimicrobial activity. For use in fiber structures, several parameters must be controlled by incorporating additives to achieve desirable porosity and surface area for wound-dressing applications, such as polymer templates, metal nanoparticles, and functional groups as crosslinking agents. These compounds provide adequate control over porosity and absorptivity, which can be combined to achieve desirable conditions for gas exchange and microbial capture in the resulting electrospun fibers. In this review, the potential and bottlenecks for the scalability and industrial application of chitosan-based biomedical fibrillar prototypes are discussed, underscoring the relevance of toxicological assays in elucidating their potential across several areas, including food packaging, smart dressings, controlled-release systems, and antimicrobial coatings.

Antibody-drug conjugates in the treatment of breast cancer

Andrezza Furquim da Cruz — 2026-07-30

Breast cancer is one of the most common causes of death in women and requires therapies that are both more precise and less toxic. Recently, antibody–drug conjugates (ADCs) have emerged as a promising strategy by selectively direct cytotoxic agents to tumor cells. The aim of this review was to investigate the efficacy, safety, and limitations of these antibodies in breast cancer treatment, and discuss their future perspectives and clinical challenges such as resistance and toxicity. This narrative review is based on a search of Pubmed, Scielo, Science Direct and INCA databases, including clinical and preclinical studies and reviews that have investigated the mechanisms of action, efficacy, and safety of ADCs over the last 15 years. Evidence from clinical trials suggests that therapy may prolong survival and reduce toxicity compared to conventional treatments, as demonstrated in clinical trials in HER2+ and TNBC patients. However, the occurrence of adverse events, resistance to therapy, and challenges in conjugating the components point to the need for optimized approaches. Overall, the results suggest that despite the challenges, this technology represents a significant advance in breast cancer therapy and that the integration of combined and personalized strategies may enhance antibody efficacy, overcome current barriers and contribute to better clinical outcomes.

Silver(I) tenoxicam complex: In vitro valuation of the antiproliferative activity over B16 melanoma cell line using electrochemotherapy

Felipe Alves de Oliveira Pires — 2026-07-03

Cancer is one of the leading causes of mortality and melanoma is one of the deadliest skin cancers. However, it is a potentially curable condition if diagnosis and treatment occur early. Electrochemotherapy is a therapeutic modality for local control against various types of neoplasia. It is a technique that uses the combination of electroporation, which allows the entry of molecules generally not permeable to the plasma membrane through electrical pulses, and chemotherapy drugs. The objective of this work is the synthesis and characterization of a silver metal complex, using tenoxicam (Ag-TNX) as a ligand, and to evaluate the antiproliferative effects on melanoma tumor cells in vitro, replacing conventional chemotherapy drugs used by the electrochemotherapy technique. Complex characterization tests were carried out, such as FTIR, thermogravimetric analysis and elemental analysis, as well a cytotoxicity tests, application of electroporation associated with the Ag-TNX complex in vitro and determination of absorption of the agent through the Franz cell. The Ag-TNX agent showed antibacterial activity over S. aureus ATCC 25924, E. coli EC 958, E. coli BR43, and P. aeruginosa ATCC 27853, and superior antiproliferative effect in the application of electroporation compared to the isolated Ag-TNX, demonstrating promising results for future expansion of therapeutic arsenal of antineoplastic and antibacterial agents.